Latest Conference Articles

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Data presented at ADA 2021 supports the noninferiority of faricimab to aflibercept.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.

Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.

Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.

Direct optical endoscopy are often underutilized in screenings for EAC.

Data show patients with IBD and pathogen produced a unique pathogen-specific microbiome.

Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.

Sucrase isomaltase deficiency is often overlooked symptom in adult patients with IBS-D.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.

Data show adverse events occurred in 6.67% in the cohort of patients with IBD.

Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.

About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.

Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.

The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.

Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.

Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.

Ulcerative colitis patients with fatigue are more likely to be unemployed, have moderate or severe disease, and higher Mayo scores.

Data show males, patients with high BMI correlated with higher FAST score in HCV care.

Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.

Data show a 23.5% increase in influenza vaccination rates.

Data show biologic therapy was not associated with ICU admission or death due to infection.

C difficile and sepsis infections can be especially difficult to treat.